PATH To Pay FDA $480,000 To Speed Creation Of Pneumococcal Vaccine For Developing World
The FDA on MondayÂ said it’s entering into a collaboration with the nonprofit group PATH “to speed creation of a pneumococcal vaccine for children in developing nations,” United Press International reports (2/1).
“The bacteria, Streptococcus pneumoniae, can cause fatal infections of the ear, lungs, blood and brain; worldwide, it kills almost one million children a year,” the New York Times writes. According to the FDA, PATH, which receives funding from the Bill & Melinda Gates Foundation, will payÂ the agencyÂ $480,000 to perform a key step needed to build the vaccine, the NewÂ York Times reportsÂ (McNeil, 2/1).
According to an FDAÂ press release, its goal “is to improve the efficiency of a key technology in the development of pneumococcal conjugate vaccine candidates. The technology is used to link a piece of the bacteriumâ€™s surface coating, a polysaccharide made up of long chains of sugars, to a special molecule called a carrier protein in a process called conjugation. When carrier proteins are joined with the polysaccharides, they significantly increase the strength of the immune response.”Â Â (2/1).Â
TheÂ New York Times reports thatÂ “the work is being done under a law that lets federal laboratories speed outside research in some cases. … Ultimately, the plan is for the vaccine to be manufactured by the China National Biotec Group, which makes 80 percent of Chinaâ€™s vaccines, and the hope is that it will be approved by the World Health Organization” (2/1).